MoonLake Immunotherapeutics (MLTX)
MLTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MLTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001821586 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $379.7M cash; operating cash flow -$61.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 85,106,685 (2026-11-01). | Cover page 2026-11-01 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, Santa Clara, California, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $99K, sold $81.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$79.5M | -$63.4M | $379.7M | $100.0M | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$61.8M | -$55.6M | $477.9M | $99.5M | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | Not filed | -$69.7M | -$66.3M | $298.5M | $99.0M | Needs four quarters | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | Not filed | -$62.4M | -$58.8M | $334.5M | $74.1M | Needs four quarters | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | Not filed | -$69.7M | -$44.5M | $350.7M | $73.7M | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$55.2M | -$54.5M | $306.7M | $73.4M | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | Not filed | -$39.9M | -$38.1M | $271.6M | $73.0M | Needs four quarters | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | Not filed | -$45.6M | -$48.5M | $180.4M | $0 | Needs four quarters | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3ASR | 2026-08-10 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 331 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.4% |
| 1 month | +20.1% |
| 3 months | -24.2% |
| Year to date | -5.2% |
| 1 year | -0.5% |
| From 52-week high | -43.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CYRX | CryoPort Inc. | $19.80 | -0.45% | $1.0B |
| SVRA | Savara Inc. | $4.46 | -3.77% | $985.1M |
| JBIO | Jade Biosciences Inc. | $15.34 | -4.99% | $975.3M |
| SPTX | Seaport Therapeutics Inc. | $19.12 | -4.30% | $1.0B |
| VSTM | Verastem Inc. | $7.70 | -5.87% | $970.3M |
| MTRI | Mentari Therapeutics Inc. | $19.87 | +6.83% | $1.0B |
| ANRO | Alto Neuroscience Inc. | $27.12 | -8.19% | $1.1B |
| HROW | Harrow Inc. | $29.09 | -3.42% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier